Hydralazine-induced tumor hypoxia: A potential target for cancer chemotherapy

Journal of the National Cancer Institute

Volumn 81, Issue 8, 1989, Pages 618-622

  Chaplin, D J ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; HYDRALAZINE; MITOMYCIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR HYPOXIA;

ANIMAL; ANTINEOPLASTIC AGENTS; AZIRIDINES; DRUG SYNERGISM; FEMALE; HYDRALAZINE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MISONIDAZOLE; MITOMYCINS; NEOPLASMS, EXPERIMENTAL; REGIONAL BLOOD FLOW; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024500292     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/81.8.618     Document Type: Article

References (33)

1. ALGIRE GH, LEGALLAIS FY: Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumors. J Natl Cancer Inst 12:399-421, 1951
2. CATER DB, GRIGSON CMB, WATKINSON DA; Changes of oxygen tension in tumors induced by vasoconstrictor and vasodilator drugs. Acta Radiol 58:401-408, 1962
3. CHAN RC, BABBS CF, VETTER RJ, ET AL: Abnormal response of tumor vasculature to vasoactive drugs. JNCI 72:145-150, 1984
4. CHAPLIN DJ, ACKER B: The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU 1069: Evidence for therapeutic gain. Int J Radiat Oncol Biol Phys 13:579-585, 1987
5. KNAPP WH, DEBATIN J, LAYER K, ET AL: Selective drug induced reductions of blood flow in tumor transplants. Int J Radiat Oncol Biol Phys 11:1357-1366, 1985
6. VOORHEES WD, BABBS CF: Hydralazine enhanced selective heating of transmissible venereal tumor implants in drugs. Eur J Cancer Clin Oncol 19:1027-1033, 1982
7. EKELUND L, LAURIN S, LUNDERQUIST A: Comparison of a vasoconstrictor and a vasodilator in pharmacoangiography of bone and soft-tissue tumors. Radiology 122:95- 99, 1977
8. JONSSON K, DESANTOS LA; WALLACE S, ET AL: Prostaglandin E, (PGE,) in angiography of tumors of the extremities. AJR 130:7-11, 1978
9. JOHNSTON BM: The use of radioactive microspheres to compare the effects of hydralazine, guanethidine and skF 24260 on the redistribution of cardiac output in anaesthetized rabbits. Br J Pharmacol 55:393- 402, 1975
10. ALBERT A; Selective Toxicity, 6th ed. London; Chapman Hall, 1979
11. BURGEN ASV, MITCHELL JF: Gaddum's Pharmacology. Oxford; Oxford Univ Press, 1975
12. CATER DB, SILVER IA: Quantitative measurements of oxygen tension in normal tissues and in patients before and after radiotherapy. Acta Radiol 53:233-256, 1960
13. VAUPEL PW, FRINAK S, BICHER HL Heterogenous oxygen partial pressure and pH < distribution in C3H mouse mammary adenocarcinoma. Cancer Res 41:2008-2013, 1981
14. OKUNIEFF P, KALUNOWSKI F, VAUPEL P, ET AL: Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31Pnuclear magnetic resonance spectroscopy. J Natl Cancer Inst 80:745-750, 1988
15. STRATFORD U, O'NEILL P, SHELDON PW, ET AL: RSU 1069: A nitroimidazole containing an aziridine group: Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 35:105-110, 1986
16. CHAPLIN DJ, DURAND RE, STRATFORD LI, ET AU The radiosensitizing and toxic effects of RSU 1069 on hypoxic cells in a murine tumor. Int J Radiat Oncol Biol Phys 12:1091-1095, 1986
17. WORKMAN P, MORGAN JE, TALBOT K, ET AL: CB 1954 revisited. EL Toxicity and antitumor activity. Cancer Chemother Pharmacol 165-14, 1986
18. MANDEL HG, CONNORS RA, MELZACK DH, ET AL: Studies on the mechanism of action of 5-aziridinyl, 2, 4-dinitrobenzamide in tumor ceUs. Cancer Res 34:275-280, 1974
19. KENNEDY KA, ROCKWELL S, SARTORELU AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40:2356-2360, 1980
20. RAUTH AM, MOHINDRA JK, TANNOCK IF: Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res 43:4154-4158, 1983
21. TEICHER BA, LAZO JS, SARTORELU AC: Classification of antineoplastic agents by their selective toxicities towards oxygenated and hypoxic tumor cells. Cancer Res 41:73- 81, 1981
22. COURTENAY VD: A soft agar clonogenic assay for Lewis lung and B16 melanoma taken directly from the mouse. Br J Cancer 34:39-45, 1976
23. SHELDON PW, HILL SA: Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumor in mice. Br J Cancer 35:795-808, 1977
24. MOULDER JE, ROCKWELL S: Hypoxic fractions of solid tumors: Experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10:695-712, 1984
25. CHAPLIN DJ, SHELDON PW, STRATFORD IJ, ET AL: Radiosensitization in vivo: A study with an homologous series of 2- nitroimidazoles. Int J Radiat Biol 44:387- 398, 1983
26. CHAPUN DJ: Post irradiation modification of tumor blood flow. A method to increase the effectiveness of chemical adiosensitizers. Radiat Res 115:292-302, 1988
27. TROTTER MJ, ACKER BD, CHAPUN DJ: Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys. In press
28. WIIG H, GADEHOLT G: Interstitial fluid pressure and hemodynamics in a sarcoma implanted in the rat tail. Microvas Res 29:176-189, 1985
29. JAW R: Transport of molecules in the tumor interstitium: A review. Cancer Res 47:3039-3050, 1987
30. VOEGTUN C, FITCH RH, KAHLER H: Experimental studies on cancer. US Nad Int Health Bull 164:1-14, 1935
31. MIKKELSON RB: Extracellular pH and weak acid/weak base uptake and cytotoxicity. Int J Radiat Oncol Biol Phys 8:1846, 1982
32. ROTIN D, ROBINSON B, TANNOCK IF: Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: Potential implication for cell death in tumors. Cancer Res 46:2821-2826, 1986
33. CHAPUN DJ, ACKER B, OUVE PL: Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. In press